Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Results
-
Prophylaxis of Influenza in Infants and Children Approved as an Additional Indication of Anti-influenza Drug Tamiflu®
[PDF 190KB] -
Regarding the Incidence of Insider Trading on Chugai Stock
[PDF 21KB] -
Organizational Restructuring and Personnel Changes
[PDF 83KB] -
Conclusion of a license agreement between BioComber and Chugai on patents related to PURESYSTEM®
[PDF 40KB] -
Regarding Today's Media Reporting
[PDF 21KB] -
Chugai Revises Corporate Advertisement for First Time in Four Years
[PDF 248KB] -
ACTEMRA Improves Signs and Symptoms in Children with Systemic Onset Juvenile Idiopathic Arthritis (sJIA)
[PDF 100KB] -
Recombinant Human Erythropoietin, Epogin® Injection
[PDF 172KB]
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia -
Chugai Presents an Anti-Cancer Charity Concert, "Christmas Concert in Yokohama Featuring Star Philharmonic Chorus"
[PDF 656KB] -
Chugai Presents
[PDF 172KB]
"Volunteer for Life: Jose Carreras Christmas Concert" as the Special Co-Sponsor -
Anti-Malignancy Agent Avastin®
[PDF 76KB]
Obtained Approval for Additional Indication of Non-Small Cell Lung Cancer -
Notice Concerning the Passing Away of a Chugai Pharmaceutical Director
[PDF 172KB] -
New Drug Application Filed for Eldecalcitol, An Active Vitamin D3 Derivative
[PDF 46KB] -
ACTEMRA inhibits progression of joint destruction in RA patients by over 80% compared to methotrexate alone
[PDF 69KB] -
Anti-Malignancy Agent/Anti-VEGF Humanized Monoclonal Antibody, Avastin®
[PDF 52KB]
Application for Approval of Additional Indication of Breast Cancer -
F. Hoffmann-La Roche Announces Third Quarter Sales 2009
[PDF 26KB] -
Revision of Financial Outlook for Fiscal Year 2009
[PDF 47KB]
(January 1 - December 31, 2009) -
Contribution of Para-transit Vehicles to Welfare Services
[PDF 103KB] -
Establishment of the Chugai Academy for Advanced Oncology (CHAAO)
[PDF 53KB] -
RoACTEMRA filed in Europe for the Inhibition of Joint Damage and Improvement in Physical Function in Rheumatoid Arthritis
[PDF 59KB] -
Anti-Cancer Agent Xeloda® and Avastin®
[PDF 61KB]
Obtained Approval for Additional Indication of Colorectal Cancer -
Antineoplastic Agent / Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Tarceva®
[PDF 53KB]
Application for Approval of Additional Indication of Pancreatic Cancer -
Chugai Displays, "Giant Colon", A Giant Size Balloon Art at "Relay for Life 2009"
[PDF 94KB] -
Organizational Restructuring and Personnel Changes
[PDF 130KB] -
Supply Plan of "Tamiflu®" Anti-influenza Drug
[PDF 71KB] -
Reconstruction Support for Devastating Typhoon Disaster Area in the Republic of China
[PDF 171KB] -
Organizational Restructuring and Personnel Changes
[PDF 84KB] -
Update on FDA Registration of Actemra®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody for Rheumatoid Arthritis
[PDF 28KB] -
F. Hoffmann-La Roche Announces 2009 Half Year Results
[PDF 70KB] -
Chugai Files NDA for a Renal Anemia Agent R744
[PDF 20KB] -
Primary Endpoint Achieved in Phase III Clinical Trial of Epogin® in Chemotherapy Induced Anemia
[PDF 22KB] -
New Developments for "CHUGAI ONCOLOGY": Establishment of "Cancer Information Guide," a Website for Patients
[PDF 855KB] -
Determination of Terms and Conditions of Stock Options as Stock-based Compensation (Stock Acquisition Rights)
[PDF 16KB] -
Chugai to Absorb Wholly-Owned Subsidiary
[PDF 41KB] -
Issuance of Stock Options as Stock-based Compensation(Stock Acquisition Rights)
[PDF 36KB] -
Approval of Partial Change of API Manufacturing Method and Pharmaceutical Formulation of the Recombinant Human Erythropoietin "Epogin® Injection"
[PDF 52KB] -
F. Hoffmann-La Roche Announces First Quarter Sales 2009
[PDF 17KB] -
Determination of Terms and Conditions of Common Stock Options (Stock Acquisition Rights)
[PDF 36KB] -
Notice of Issuance of Common Stock Options (Stock Acquisition Rights)
[PDF 52KB] -
Relationship with the Parent Companies and Related Parties
[PDF 127KB] -
License Agreement with Romark Laboratories and Development of Nitazoxanide in Japan
[PDF 131KB] -
Notification Concerning Dividend Distribution
[PDF 43KB] -
Appointments of a New Director and an Auditor
[PDF 61KB] -
Abolishment of Directors' Retirement Benefits and Granting of Stock Options
[PDF 37KB] -
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2008
[PDF 68KB] -
Loss of personal information as a result of having a sales vehicle stolen
[PDF 72KB] -
RoACTEMRA®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Approved in EU for Rheumatoid Arthritis
[PDF 64KB]